Aisa Gelal

Dr. Aisa Gelal

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Elena ChitoranElena Chitoran
Elena Chitoran
VRVlad Rotaru
Vlad Rotaru
MMMadalina Nicoleta Mitroiu
Madalina Nicoleta Mitroiu
CDCristiana-Elena Durdu
Cristiana-Elena Durdu
RBRoxana-Elena Bohiltea
Roxana-Elena Bohiltea
Laurentiu SimionLaurentiu Simion
Laurentiu Simion
(1) Background: Currently, an increasing number of women postpone pregnancy beyond the age of 35. Gynecological cancers affect a significant proportion of women of reproductive age, necessitating the development of fertility preservation methods to fulfill family planning. Consequently, providing treatment options that preserve fertility in women diagnosed with gynecological cancers has become a crucial component of care for survivors. (2) Methods: We conducted an extensive search of relevant scientific publications in PubMed and Embase databases and performed a narrative review, including high-quality peer-reviewed research on fertility after being treated for gynecologic cancers, reporting pregnancy rates, birth rates, and pregnancy outcomes in cancer survivors as well as therapeutic options which partially preserve fertility and methods for obtaining a pregnancy in survivors. (3) Discussion: The medicine practiced today is focused on both treating the neoplasm and preserving the quality of life of the patients, with fertility preservation being an important element of this quality. This leads to an improved quality of life, allowing these women to become mothers even in the seemingly adverse circumstances posed by such a pathology. However, although there are guidelines on female fertility preservation in the context of neoplasms, an analysis shows that physicians do not routinely consider it and do not discuss these options with their patients. (4) Conclusions: Advancements in medicine have led to a better understanding and management of gynecological neoplasms, resulting in increased survival rates. Once the battle against these neoplasms is won, the issue of preserving the quality of life for these women arises, with fertility preservation being an important aspect for women who have not yet fulfilled their family planning desires at the time of diagnosis. It is important for patients to be informed about the available options for fertility preservation and to be encouraged to make informed decisions in collaboration with their medical team. Standardized recommendations for onco-fertility into guidelines should be taken into consideration in the future.

19 September 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Elena ChitoranElena Chitoran
Elena Chitoran
VRVlad Rotaru
Vlad Rotaru
AGAisa Gelal
Aisa Gelal
Sinziana IonescuSinziana Ionescu
Sinziana Ionescu
Giuseppe GulloGiuseppe Gullo
Giuseppe Gullo
Laurentiu SimionLaurentiu Simion
Laurentiu Simion
Background/Objectives: The use of artificial intelligence (AI) in oncology has the potential to improve decision making, particularly in managing the risk associated with targeted therapies. This study aimed to develop and validate a machine learning-based clinical decision support system (CDSS) capable of predicting complications associated with Bevacizumab or its biosimilars and to translate the resulting predictive model into a clinically applicable tool. Methods: A prospective observational study was conducted on 395 records from patients treated with Bevacizumab or biosimilars for solid tumors. Pretherapeutic variables, such as demographic data, medical history, tumor characteristics and laboratory findings, were retrieved from medical records. Several machine learning models (logistic regression, Random Forest, XGBoost) were trained using 70/30 and 80/20 data splits. Their predictive performances were compared using accuracy, AUC-ROC, sensitivity, specificity, F1-scores and error rate. The best-performing model was used to derive a logistic-based risk score, which was further implemented as an interactive HTML form. Results: The optimized Random Forest model trained on the 80/20 split demonstrated the best balance between accuracy (70.63%), sensitivity (66.67%), specificity (73.85%), and AUC-ROC (0.75). The derived logistic risk score showed good performance (AUC-ROC = 0.720) and calibration. It identified variables, such as age ≥ 65, anemia, elevated urea, leukocytosis, tumor differentiation, and stage, as significant predictors of complications. The final tool provides clinicians with an easy-to-use, offline form that estimates individual risk levels and stratifies patients into low-, intermediate-, or high-risk categories. Conclusions: This study offers a proof of concept for developing AI-supported predictive tools in oncology using real-world data. The resulting logistic risk score and interactive form can assist clinicians in tailoring therapeutic decisions for patients receiving targeted therapies, enhancing the personalization of care without replacing clinical judgment.

19 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Elena ChitoranElena Chitoran
Elena Chitoran
VRVlad Rotaru
Vlad Rotaru
Sinziana IonescuSinziana Ionescu
Sinziana Ionescu
AGAisa Gelal
Aisa Gelal
CCCristina Mirela Capsa
Cristina Mirela Capsa
Laurentiu SimionLaurentiu Simion
Laurentiu Simion
Overall, it is estimated that more than 3,500,000 patients have received Bevacizumab as part of systemic oncologic treatment. Bevacizumab and its biosimilars are currently marketed in over 130 countries. Given the wide usage of Bevacizumab in current oncological practice, it is very important to compare the “real-world” results to those obtained in controlled clinical trials. This study aims to describe the clinical experience of using Bevacizumab in a large cohort of cancer patients in “non-controlled real-world” conditions with regard to effectiveness, safety, and cost of therapy. Methods: For this purpose, we conducted an open, observational, retrospective study involving all patients treated for solid malignant tumors in the Bucharest Institute of Oncology with “Prof. Dr. Al. Trestioreanu” with Bevacizumab-based systemic therapy, between 2017 and 2021. Results: The study consisted of 657 treatment episodes in 625 patients (F/B = 1.62/1, with a median age of 57.6 years) which were treated for malignant tumors (majority colorectal, non-small cell lung, ovarian, and breast cancer). First-line treatment was administered in 229 patients, and the rest received Bevacizumab as second or subsequent lines of treatment. The overall response rate to Bevacizumab-based therapies was around 60–65% across all indication except for subsequent treatment lines in colorectal and ovarian cancers, where lower values were recorded (27.1%, and 31.5% respectively). Median PFS for the entire cohort was 8.2 months (95% CI 6.8–9.6), and the median OS was 13.2 months (95% CI 11.5–14.9). Usual bevacizumab-related toxicities were observed, including bleeding, hypertension, wound-healing complications, gastrointestinal perforation, other types of fistulas, septic complications, and thromboembolic events. Although the clinical benefits are undeniable, the addition of Bevacizumab to standard chemotherapy increased the overall treatment cost by 213%. Conclusions: Bevacizumab remains a high-cost therapy, but it can add to clinical benefits (like overall survival, progression-free survival, and response rate) when used in conjunction with standard chemotherapy. Similar results as those presented in various controlled trials are observable even on unselected cohorts of patients in the uncontrolled conditions of “real-world” oncological practice. Off-label usage is encountered in clinical practice, and this aspect should be monitored given the potential adverse effects of the therapy.

17 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VRVlad Rotaru
Vlad Rotaru
Elena ChitoranElena Chitoran
Elena Chitoran
AGAisa Gelal
Aisa Gelal
Giuseppe GulloGiuseppe Gullo
Giuseppe Gullo
Daniela Cristina StefanDaniela Cristina Stefan
Daniela Cristina Stefan
Laurentiu SimionLaurentiu Simion
Laurentiu Simion
Background/Objective: Pelvic exenteration (PE) is a radical procedure with significant physical and psychosocial consequences. Despite increasing survival rate following PE, quality of life (QoL) outcomes remain inconsistently reported and poorly understood in clinical practice. This study aims to explore: (1) What is the current evidence on QoL after pelvic exenterations? and (2) How do patient-reported experiences align with or differ from findings in the literature? Methods: We conducted a mixed-methods study consisting of two components: (1) a qualitative analysis of 5 in-depth, semi-structured interviews with patients who underwent PE for advanced pelvic cancers; and (2) a narrative review of 28 quantitative and qualitative studies evaluating QoL after PE, published between 1975 and 2023, encompassing 1149 patients. Thematic analysis was performed using an interpretative phenomenological approach. Results: Qualitative findings revealed recurrent themes of identity disruption, social withdrawal, emotional resilience, and a need for personalized, preoperative information. Patients often described a mismatch between surgical expectations and lived experience, and expressed a strong desire for better psychological support and realistic communication. The review of published studies showed heterogeneous findings, with moderate recovery in global QoL scores by 6–12 months postoperatively, but persistent impairments in physical function, sexual health, and emotional well-being. Only a minority of studies included patient-reported outcomes tailored to specific domains such as body image or psychological adaptation (17.8%). Conclusions: Recovery after pelvic exenteration extends beyond physical healing and requires attention to emotional, social, and existential dimensions. Integrating psycho-oncologic support and patient-centered communication into standard care is essential. This hybrid analysis underscores the importance of addressing quality of life proactively—not only as an outcome, but as a fundamental component of survivorship care.

6 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
VRVlad Rotaru
Vlad Rotaru
Elena ChitoranElena Chitoran
Elena Chitoran
DZDaniela Luminita Zob
Daniela Luminita Zob
Sinziana IonescuSinziana Ionescu
Sinziana Ionescu
AGAisa Gelal
Aisa Gelal
Laurentiu SimionLaurentiu Simion
Laurentiu Simion
First described some 80 years ago, pelvic exenteration remain controversial interventions with variable results and ever-changing indications. The previous studies are not homogenous and have different inclusion criteria (different populations and different disease characteristics) and methodologies (including evaluation of results), making it extremely difficult to properly assess the role of pelvic exenteration in cancer treatment. This study aims to describe the indications of pelvic exenterations, the main prognostic factors of oncologic results, and the possible complications of the intervention. Methods: For this purpose, we conducted a retrospective study of 132 patients who underwent various forms of pelvic exenterations in the Institute of Oncology “Prof. Dr. Al. Trestioreanu” in Bucharest, Romania, between 2013 and 2022, collecting sociodemographic data, characteristics of patients, information on the disease treated, data about the surgical procedure, complications, additional cancer treatments, and oncologic results. Results: The study cohort consists of gynecological, colorectal, and urinary bladder malignancies (one hundred twenty-seven patients) and five patients with complex fistulas between pelvic organs. An R0 resection was possible in 76.38% of cases, while on the rest, positive margins on resection specimens were observed. The early morbidity was 40.63% and the mortality was 2.72%. Long-term outcomes included an overall survival of 43.7 months and a median recurrence-free survival of 24.3 months. The most important determinants of OS are completeness of resection, the colorectal origin of tumor, and the presence/absence of lymphovascular invasion. Conclusions: Although still associated with high morbidity rates, pelvic exenterations can deliver important improvements in oncological outcomes in the long-term and should be considered on a case-by-case basis. A good selection of patients and an experienced surgical team can facilitate optimal risks/benefits.

22 May 2024 in Medicina
Verified
Journal Article
Open access
PDF file
VRVlad Rotaru
Vlad Rotaru
Elena ChitoranElena Chitoran
Elena Chitoran
MMMadalina Nicoleta Mitroiu
Madalina Nicoleta Mitroiu
Sinziana IonescuSinziana Ionescu
Sinziana Ionescu
ANAriana Neicu
Ariana Neicu
Laurentiu SimionLaurentiu Simion
Laurentiu Simion
Background: Clear cell sarcoma (CCS) is an extremely rare form of sarcoma representing less than 1% of all soft-tissue sarcomas. It has morphological, structural, and immunohistochemical similarities to malignant melanoma, affecting young adults and equally affecting both sexes, and is usually located in the tendinous sheaths and aponeuroses of the limbs. Gastrointestinal localization is exceptional, with less than 100 cases reported thus far. The gene fusion of activating transcription factor 1 (ATF1) and the Ewing sarcoma breakpoint region 1 (EWSR1) are pathognomonic for clear cell sarcoma, representing the key to the diagnosis. CCS is an extremely aggressive tumor, with >30% having distant or lymphatic metastasis at the time of diagnostic, and it has a high recurrence rate of over 80% in the first year after diagnosis and a high tendency for metastatic dissemination. Given the rarity of this tumor, there is no standardized treatment. Early diagnosis and radical surgery are essential in the treatment of CCS both for the primary tumor and for recurrence or metastasis. Chemo-radiotherapy has very little effect and is rarely indicated, and the role of targeted therapies is still under investigation. Case presentation: We present an extremely rare case of intestinal CSS in a 44-year-old Caucasian female. The patient, asymptomatic, first presented for a routine checkup and was diagnosed with mild iron-deficiency anemia. Given her family history of multiple digestive cancers, additional investigations were requested (gastroscopy, colonoscopy, tumoral markers and imaging) and the results were all within normal limits. In the subsequent period, the patient experienced mild diffuse recurrent abdominal pain, which occurred every 2–3 months. Two years later, the patient presented with symptoms of intestinal obstruction and underwent an emergency laparotomy followed by segmental enterectomy and regional lymphadenectomy for stenotic tumor of the jejunum. Histology, immunohistochemistry, and genetic testing established the diagnosis of CCS. No adjuvant therapy was indicated. Initially, no signs of recurrence or metastasis were detected, but after 30 and 46 months, respectively, from the primary treatment, the patient developed liver metastasis and pericolic peritoneal implants treated by atypical hepatic resections and right hemicolectomy. The patient remains under observation.